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The present study aims at a platform-independent confirmation of previously obtained cDNA microarray results on inflammatory
breast cancer (IBC) using Affymetrix chips. Gene-expression data of 19 IBC and 40 non-IBC specimens were subjected to clustering
and principal component analysis. The performance of a previously identified IBC signature was tested using clustering and gene set
enrichment analysis. The presence of different cell-of-origin subtypes in IBC was investigated and confirmed using
immunohistochemistry on a TMA. Differential gene expression was analysed using SAM and topGO was used to identify the
fingerprints of a pro-metastatic-signalling pathway. IBC and non-IBC have distinct gene-expression profiles. The differences in gene
expression between IBC and non-IBC are captured within an IBC signature, identified in a platform-independent manner. Part of the
gene-expression differences between IBC and non-IBC are attributable to the differential presence of the cell-of-origin subtypes,
since IBC primarily segregated into the basal-like or ErbB2-overexpressing group. Strikingly, IBC tumour samples more closely
resemble the gene-expression profile of T1/T2 tumours than the gene-expression profile or T3/T4 tumours. We identified the
insulin-like growth factor-signalling pathway, potentially contributing to the biology of IBC. Our previous results have been validated in
a platform-independent manner. The distinct biological behaviour of IBC is reflected in a distinct gene-expression profile. The fact that
IBC tumours are quickly arising tumours might explain the close resemblance of the IBC gene-expression profile to the expression
profile of T1/T2 tumours.
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Inflammatory breast cancer (IBC) is a clinical diagnosis designated
as the T4d category in the TNM classification of the American
Joint Committee on Cancer (Singletary et al, 2002). It is a distinct
clinical subtype of locally advanced breast cancer (LABC), with a
particularly aggressive behaviour and poor prognosis (median
3-year survival of about 40%). Clinically, IBC typically presents
with rapidly progressive breast erythema, warmth, oedema and
induration, often without palpable underlying tumour mass (Kleer
et al, 2000; Lerebours et al, 2005; Dirix et al, 2006). Tumour emboli
in dermal lymphatics may be apparent on skin biopsy, but in the
absence of clinical findings do not indicate IBC (Kleer et al, 2000;
Low et al, 2004; Lerebours et al, 2005; Dirix et al, 2006). Whether
the particular clinical presentation of IBC is a reflection of a
specific biologic subtype in human breast cancer remains unclear.
Several studies have been undertaken to gain deeper insights
towards understanding the biological characteristics of IBC. At
molecular level, overexpression of RhoC GTPase and loss of WISP3
is linked to breast tumours from patients with IBC (Van Golen
et al, 1999; Kleer et al 2002). At biological level, increased
angiogenesis in breast tumours from patients with IBC was
demonstrated in several independent studies (Colpaert et al, 2003;
Van der Auwera et al, 2004). Using cDNA microarrays, Bertucci
et al (2004) and Van Laere et al (2005) identified gene-expression
signatures associated with the IBC phenotype. Using the same
expression data sets, both studies demonstrated the presence of the
same cell-of-origin breast cancer subtypes in IBC (Bertucci et al,
2005; Van Laere et al, 2006a), as was originally described for
non-IBC (Perou et al, 2000). In depth analysis of genes
differentially expressed between breast tumour samples from
patients with IBC and other breast tumour samples revealed a
potential hyperactivation of NF-kB in IBC (Van Laere et al, 2005),
which was validated and confirmed in an independent study (Van
Laere et al, 2006b).
The current study presents a follow-up study of our previous
cDNA microarray experiments comparing non-inflammatory and
inflammatory breast carcinoma using a platform-independent
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sapproach. The main focus of this study is to validate our
observation that breast tumours from patients with IBC and
breast tumours from patients without IBC have a different
gene-expression profile. In addition, the present gene-expression
data set is further explored to obtain specific biological
insights associated with the aggressive behaviour of this invasive
type of breast cancer. This is of particular importance because no
real progression has been made in treating this type of breast
cancer, with the exception of a minor improvement due to the
induction of taxanes. These novel insights might lead towards
novel targets for treatment of breast tumours from patients
with IBC.
MATERIALS AND METHODS
Patients and samples
Tumour samples were obtained from patients with breast
adenocarcinoma treated in the Breast Clinic of the General
Hospital Sint-Augustinus, Wilrijk, Belgium. Each patient gave
written informed consent. This study was approved by the Local
Institutional Review Board. All samples were stored in liquid
nitrogen within 15min after excision (median delay of 9min).
Breast tumour samples included 19 pretreatment samples of
patients with IBC, diagnosed by strictly respecting the criteria of
the American Joint Committee on Cancer (Singletary et al, 2002).
The presence of tumour emboli was, as an isolated pathological
finding, not sufficient for the diagnosis of IBC. Of the 40 non-IBC
samples, 9 represented LABC (eight T3 and one T4), 14 samples
represented T2 tumours and 17 represented T1 tumours.
Clinicopathologic characteristics for the IBC and non-IBC are
provided in Table 1.
RNA extraction, microarray hybridisation and
normalisation
RNA was extracted as described before using the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA). One T3 tumour and one T2 tumour
was sampled twice to assess the reproducibility of the gene-
expression profiling experiments. RNA from 61 samples was
hybridised onto HGU 133 plus 2.0 Affymetrix chips in collabora-
tion with the VIB Microarray Facility (O&N, UZ-Gasthuisberg,
Leuven, Belgium). Four IBC samples have already been used in our
previous genome-wide gene-expression analysis experiments (Van
Laere et al, 2005). Perfect match (PM) fluorescence intensities were
background-corrected, mismatch (MM)-adjusted, normalised and
summarised to yield log2-transformed gene-expression data using
the GCRMA algorithm. All normalisation procedures and sub-
sequent data analyses have been performed using Bioconductor in
R (www.bioconductor.org).
Data analysis
To remove data noise and reduce data dimensionality, all genes
with gene-expression data above log2 (100) in at least 25% of the
arrays were filtered in resulting in a gene list of 18182 informative
genes. Global views of the variation in gene expression among the
different breast cancer samples defined by the informative gene list
were obtained using principal component analysis. Next, 250
informative genes having the greatest s.d. were selected to perform
an unsupervised hierarchical complete linkage cluster analysis
with the Euclidean distance as similarity metric.
The presence of the five different cell-of-origin breast cancer
subtypes, originally described by Perou et al (2000) for non-IBC,
was investigated in the present data set using a centroid-mediated
classification algorithm. Detailed methodology is described in Van
Laere et al (2006a). Briefly, the intrinsic gene list was mapped onto
our informative gene list resulting in 347 informative and intrinsic
genes. For each of the five cell-of-origin subtypes, we computed the
typical expression profile for the 347 genes in the original Norway/
Stanford data set (Sorlie et al, 2003), hereafter designated centroid.
To classify our breast tumour samples, Pearson correlations were
calculated between each sample in our series and each centroid
based on the Norway/Stanford data set (Sorlie et al, 2003). A breast
tumour sample was classified according to the highest correlation
coefficient between its molecular profile and any of the calculated
centroids. Unsupervised hierarchical complete linkage clustering
and principal component analysis was applied to investigate the
reliability of the subtype classification.
Our previously described IBC signature, consisting of 756 genes
able to separate IBC from non-IBC in an unsupervised hierarchical
clustering (Van Laere et al, 2005), was mapped onto the list of
informative genes, identifying 739 common genes. Using these
genes, principal component analysis and unsupervised hierarchical
complete linkage clustering was performed to investigate common
biological themes present in this data set. The global expression
difference of the IBC signature between IBC and non-IBC was
investigated using Goeman’s global test (Goeman et al, 2004). To
investigate if our IBC signature truly reflects the difference
between IBC and non-IBC in a platform-independent manner,
gene set enrichment analysis (GSEA) was performed (Subramanian
et al, 2005). Statistical significance of the GSEA was assessed using
10000 permutations.
Nuclear factor-kB hyperactivation in IBC was investigated using
105 genes activated by NF-kB, originally described by Loercher
et al (2004) and used to demonstrate aberrant NF-kB activation in
squamous cell carcinoma. The same gene list was used by Chung
et al (2006) to describe activation of NF-kB in high-risk head and
neck squamous cell carcinoma. The NF-kB signature was mapped
onto our informative gene list resulting in 93 common genes
between the NF-kB signature and our informative gene list.
Table 1 Clinicopathological characteristics for IBC and non-IBC patients
Data set (n¼59)
Non-IBC (n¼40) IBC (n¼19) P
Age (years)
Median (range) 60 (31–89) 63 (45–78) 0.319
Histological type
Ductal 34 17 0.639
Lobular 6 2
Tumour emboli in dermal lymph vessels
Present 9 15 o0.0001
Absent 31 4
Grade
a
1 16 0 0.003
21 5 9
39 1 0
T-stadium
11 7 0 o0.0001
21 4 0
38 0
41 1 9
N-stadium
b
0 18 1 0.002
11 2 5
21 0 1 3
IBC¼inflammatory breast cancer.
aAccording to the Elston–Ellis modification of the
SBR grading system.
bThe N-stadium for patients with IBC was determined clinically.
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unsupervised hierarchical complete linkage clustering, global
testing and GSEA. Global testing and GSEA was additionally
performed for gene lists representing several NF-kB-related gene
ontology (GO) identifiers. Statistical significance of the GSEA was
assessed using 10000 permutations.
Significance analysis of microarrays (SAM; Tusher et al, 2001)
was performed to select genes with a differential gene-expression
profile between IBC and non-IBC. Choosing a d-value of 1.6, we
selected 1794 genes with a false discovery rate (FDR) lower than
0.01. This gene list was intersected with a gene list containing all
differentially expressed genes (FDRo0.05) from our previous data
set, resulting in 115 common genes. Using the topGO algorithm
(Alexa et al, 2006), these 115 common genes were analysed to
identify which molecular functions are represented within this
gene list. Significance for each individual GO-identifier was
computed by applying Fisher’s exact test on a weighted
contingency table for the specified GO-identifier.
Tissue microarray
Using the Beecher Instruments Tissue Arrayer (Beecher Instru-
ments, Silver Springs, MD, USA) a tissue microarray (TMA) was
constructed containing the same patient population as used for the
genome-wide gene-expression profiling experiments. The TMA
contained four core biopsies for every IBC and non-IBC patient.
To minimise tissue loss during microtome sectioning and
tissue transfer, the TMA was incubated for 30min at 401C.
Five-micrometre slides were cut from the TMA and immuno-
histochemistry was performed for oestrogen receptor (ER),
progesterone receptor (PR), Her2/neu oncogene (ErbB2), epider-
mal growth factor receptor (EGFR) and cytokeratin 5/6 (CK5/6).
For ER, PR, ErbB2 and EGFR, the PharmDX system (Dako,
Glostrub, Denmark) was used according to the manufacturer’s
instructions. For CK5/6 (clone D5-16 B4, Dako), TMA sections
were rehydrated through sequential changes of alcohol and
distilled water. Antigen retrieval was performed in Tris/EDTA
(pH 9) during 30min at 951C. The antigen was incubated at room
temperature at a concentration of 0.2mgml
 1. For ER and PR, a
breast tumour was regarded positive when at least 10% of the
tumour cell nuclei demonstrated protein expression. For ErbB2,
scoring was performed according to the HercepTest scoring
system. For EGFR and CK5/6, a tumour was regarded positive
when respectively membranous and cytoplasmatic staining of
tumour cells was observed.
Statistical analysis
Statistical analysis other than microarray data analysis was
performed using the SPSS 11.0. package (SPSS Inc., Chicago, IL,
USA). Correlations between the clustering output and IHC data
were calculated using a Pearson w
2 test or a Fisher’s Exact test
when appropriate. A P-value smaller than 0.05 was regarded as
significant.
RESULTS
IBC and non-IBC show a distinct gene-expression profile
Global views of the variation in gene expression among the
different breast cancer samples defined by the informative gene list
were obtained using principal component analysis. Inflammatory
breast cancer (red) and non-IBC (green and blue) specimens are
separated along the first principal component (X-axis; Figure 1A).
The IBC specimens are scattered near the right end of the X-axis,
whereas the non-IBC specimens scattered around the middle and
near the left end of the X-axis. Strikingly, the global gene-
expression pattern of IBC (red) specimens more closely resembled
the global gene-expression pattern of T1 or T2 tumours (blue)
instead of the global gene expression of LABC (T3 or T4 tumours,
green).
Two hundred and fifty genes having the greatest s.d. were
submitted to unsupervised hierarchical complete linkage cluster-
ing analysis. The clustering output is visualised in Figure 1B.
Importantly, replicate RNA samples from the same breast tumours
clustered on terminal branches, indicating the global reproduci-
bility of our microarray experiment. For further statistical analysis,
replicate samples are regarded as one sample. Two major sample
clusters have been identified. A first sample cluster (left) is
enriched in IBC specimens (17 out of 29), whereas a second
sample cluster (right) was enriched in non-IBC specimens (28 out
of 30; Pearson w
2, Po0.0001).
Identification of the cell-of-origin subtypes in IBC and
non-IBC
The presence of different breast cancer cell-of-origin subtypes has
been repeatedly observed in IBC (Bertucci et al, 2005; Van Laere
et al, 2006a). We have shown that IBC primarily segregates into the
basal-like or ErbB2-overexpressing subgroups (Van Laere et al,
2006a). We have investigated the presence of the different cell-of-
origin subtypes in the current data set using a centroid-mediated
clustering algorithm. For further statistical analysis, replicate
samples were regarded as one sample. Five out of seven (71%)
basal-like, 8 out of 12 (67%) ErbB2-overexpressing, 1 out of 19
(5%) luminal A, 3 out of 8 (38%) luminal B and 2 out of 13 (15%)
normal-like breast tumours were IBC samples. Altogether, 13 out
of 19 IBC samples belonged to the combined basal-like and ErbB2-
overexpressing subtype, whereas only 6 out of 40 non-IBC
belonged to the combined basal-like and ErbB2-overexpressing
cluster (Pearson w
2; Po0.0001). These classification results have
been confirmed using unsupervised hierarchical complete linkage
clustering analysis (Figure 2A) and principal component analysis
(Figure 2B).
The classification of the breast tumour into the different cell-
of-origin subtypes was validated using IHC for ER, PR, ErbB2,
EGFR and CK5/6 using a TMA containing core biopsies of each
breast tumour in our gene-expression data set. Microphotographs,
demonstrating IHC staining results for each of the above-
mentioned markers, are visualised in Figure 2C. Within the
combined luminal A, luminal B and normal-like group, we
identified 37 out of 40 breast tumour with ER protein expression,
whereas in the remaining two subtypes, only 5 out of 19 breast
tumours with ER expression were identified (Pearson w
2,
Po0.0001). For PR, similar results were obtained. ErbB2 protein
overexpression was found in 8 out of 12 breast tumours classified
as belonging to the ErbB2-overexpressing subtype, whereas for the
remaining subtypes only 4 out of 47 breast tumour displayed
ErbB2 overexpression (Pearson w
2, Po0.0001). For the breast
tumours classified as basal-like tumours, 5 out of 7 had no ER, PR
or ErbB2 overexpression (‘triple negative’), whereas only 4 out of
52 non-basal-like breast tumours were triple negative (Pearson w
2,
Po0.0001). In addition, 5 out of 7 and 4 out of 7 basal-like
tumours showed respectively EGFR and CK5/6 overexpression
compared to only 3 out of 52 and 5 out of 52 in the non-basal-like
breast tumours (Pearson w
2, respectively Po0.0001 and 0.001).
Platform-independent validation of our IBC signature
Previously, we described an IBC signature, based on the expression
of 756 genes able to separate IBC from non-IBC using a cluster
analysis (Van Laere et al, 2005). To perform a platform-
independent validation of our IBC signature, we submitted the
present data set to unsupervised hierarchical complete linkage
clustering using 739 genes in common between the IBC signature
and the informative gene list. The resulting dendrogram is
Confirmation of distinct IBC gene-expression profile
S Van Laere et al
1167
British Journal of Cancer (2007) 97(8), 1165–1174 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
svisualised in Figure 3A. We identified one sample cluster,
mainly enriched in IBC specimens (12 out of 18). These results
have been confirmed using principal component analysis (data not
shown).
Next, we investigated if the IBC signature truly captures the
difference between IBC and non-IBC. Therefore, we investigated if
the genes, belonging to the IBC signature, were significantly
overrepresented in the list of differentially expressed genes
between IBC and non-IBC obtained using the present data set.
Using the GSEA algorithm, we obtained a P-value of 0.048 for the
IBC signature. Moreover, using the Goeman’s global test, we
demonstrated that the global expression pattern of the IBC
signature is significantly related to the difference between IBC
and non-IBC (Po0.0001).
50
0
–50
–100
–100 –50 0 50 100
Figure 1 Principal component analysis using a list of 18.182 informative genes was performed to obtain global views of the variation in gene expression
among the different breast cancer samples (A). Inflammatory breast cancer samples are colour-coded red, non-IBC T1 or T2 tumours are colour-coded blue
and non-IBC T3 or T4 tumours are colour-coded green. The first principal component is represented by the X-axis, whereas the Y-axis represents the
second principal component. Inflammatory breast cancer and non-IBC samples are separated along the first principal component. Unsupervised hierarchical
complete linkage clustering was performed using 250 informative genes having the greatest s.d. (B). Gene-expression data for these 250 genes are
represented in matrix format, with rows indicating genes and columns indicating samples. Overexpressed genes colour-coded red and underexpressed
genes colour-coded blue. Colour saturation indicates the level of overexpression or repression. Tumour class is represented by a colour-coded bar
underneath the dendrogram (IBC¼dark blue; non-IBC¼light blue). Replicate samples are indicated by blue rectangles. Two sample clusters have been
identified, one cluster enriched in IBC specimens (17 out of 29) and other cluster enriched in non-IBC specimens (28 out of 30; Pearson w
2; Po0.0001).
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Figure 2 Unsupervised hierarchical complete linkage clustering was performed using 347 intrinsic genes (A). Gene-expression data for these 347 genes
are represented in matrix format, with rows indicating genes and columns indicating samples. Overexpressed genes are colour-coded red and
underexpressed genes are colour-coded blue. Colour saturation indicates the level of overexpression or repression. Branches of replicate samples are
indicated using a blue rectangle. Cell-of-origin subtype classification for each breast tumour is indicated underneath the dendrogram. Cell-of-origin subtypes
are colour-coded as follows: luminal A (yellow), luminal B (purple), normal-like (green), ErbB2-overexpressing (blue) and basal-like (red). Two sample
clusters have been identified, one sample cluster containing most basal-like, ErbB2-overexpressing and luminal B samples (24 out of 27) and other sample
cluster containing most luminal A and normal-like samples (30 out of 32; Pearson w
2; Po0.0001). Inflammatory breast cancer samples (16 out of 19) are
contained within the first sample cluster and 30 out of 40 nIBC samples are contained within the second sample cluster (Pearson w
2; Po0.0001). Principal
component analysis using the same gene set was performed (B) and similarly colour-coded. The distinct cell-of-origin subtype clusters are clearly visible,
confirming our initial centroid-mediated classification. The ERþ cell-of-origin subtypes (luminal A, luminal B and normal-like) are separated from the ER 
cell-of-origin subtypes (basal-like and ErbB2-overexpressing) along the X-axis (first principal component), implicating ER expression as the major
discriminator within the intrinsic gene list. The classification was validated using IHC for ER, PR, ErbB2, EGFR and CK5/6 on a TMA containing core biopsies
from the same patients as those used for the genome-wide gene-expression analysis. Microphotographs, visualising staining results are displayed in( C).
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Figure 3 Unsupervised hierarchical complete linkage clustering was performed using a previously identified IBC signature. The resulting dendrogram is visualised (A). Tumour labels (IBC or nIBC) are
printed immediately beneath each branch. The height of the branches, indicated in the Y-axis, is a measure for dissimilarity between clusters. Clusters generated at a higher level in the dendrogram are more
dissimilar than clusters generated at a lower level in the dendrogram. Branches from replicate samples are indicated using a blue rectangle. One sample cluster, particularly enriched in IBC specimens (12 out
of 18) is indicated using a red rectangle. The dendrogram resulting from unsupervised hierarchical complete linkage clustering, performed using an NF-kB signature is visualised in (B). Again, tumour labels
(IBC or nIBC) are printed immediately beneath each branch and replicate samples are indicated using a blue rectangle. One IBC-rich cluster (17 out of 33; right of the red line) and one IBC-poor (2 out of 26)
cluster (left of the red line) was identified (Pearson w
2; Po0.0001). Oestrogen receptor status and combined EGFR and/or ErbB2 overexpression are indicated beneath the dendrogram using colour-coded
bars (yellow: ER ; purple: ERþ; orange: no EGFR or ErbB2 overexpression; light blue: EGFR and/or ErbB2 overexpression). The IBC-rich cluster contained 16 out of 33 ER  and 17 out of 33 EGFR and/or
ErbB2þ breast tumour specimens compared to only 1 out of 26 ER  and 1 out of 26 EGFR and/or ErbB2þ breast tumour specimens in the IBC-poor cluster (Pearson w
2; respectively Po0.0001 and
0.0001).
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Previously, we have demonstrated that NF-kB hyperactivation is a
common feature of IBC (Van Laere et al, 2006b). To investigate
NF-kB hyperactivation in the current data set, we applied
unsupervised hierarchical complete linkage clustering using an
NF-kB signature as input gene list (Loercher et al, 2004). The
dendrogram is visualised in Figure 3B. Replicate samples
were regarded as one sample. We identified two sample clusters,
one sample cluster mainly enriched in non-IBC specimens (24 out
of 26; blue), and one sample cluster containing nearly all IBC
specimens (17 out of 33; grey; Pearson w
2, P 0.0002). The global
expression pattern of the NF-kB signature was linked to the
difference between IBC and non-IBC (Goeman’s global test,
P¼0.0003). However, genes belonging to the NF-kB signature
were not significantly overrepresented in the list of differentially
expressed genes between IBC and non-IBC obtained using the
current data set (GSEA, P¼0.293). These results were confirmed
using the same analyses for gene lists derived from NF-kB-related
GO identifiers (Table 2).
Interestingly, unsupervised hierarchical complete linkage clus-
tering, using the NF-kB signature as input gene list, performed
better in separating ERþ from ER  breast tumour specimens.
The IBC-rich sample cluster contains 16 out of 33 ER  breast
tumour specimens, whereas the IBC-poor sample cluster contains
only 1 out of 26 ER  breast tumour specimen (Pearson w
2,
Po0.0001; Figure 3B). In addition, nearly all breast tumours
having EGFR and/or ErbB2 overexpression were contained in the
IBC-rich sample cluster: 17 out of 33 EGFR and/or ErbB2-positive
samples in the IBC-rich cluster versus 25 out of 26 EGFR- and
ErbB2-negative samples in the IBC-poor cluster (Pearson w
2,
Po0.0001; Figure 3B).
Gene ontology analysis of commonly overexpressed genes
To gain deeper insights into the biology of IBC, we selected 1794
differentially expressed genes using SAM (Figure 4A) and
intersected this gene list with differentially expressed genes
obtained from the former data set. We identified 115 commonly
overexpressed genes in either IBC or non-IBC. The 20 top-ranked
molecular functions, significantly overrepresented in the gene list
of commonly overexpressed genes, are listed in Figure 4B. Among
the 20-top ranked GO identifiers related to molecular functions, 3
GO identifiers were related to insulin-like growth factor signalling
(GO:0005010, GO:0005520, GO:0043560). Gene set enrichment
analysis showed that genes belonging to GO:0005010 are sig-
nificantly overrepresented among the differentially expressed
genes (Figure 4B). In addition, ‘phosphoinositide 3-kinase binding’
(GO:0043548), a molecular function implicated in PI3K signalling,
was identified.
DISCUSSION
Inflammatory breast cancer is a specific and aggressive form of
LABC, among others characterised by an elevated metastatic and
angiogenic potential (Van der Auwera et al, 2004). A better
understanding of the specific biology of the breast tumours
associated with IBC might lead to improved therapeutic modalities
as well as to new and sensitive diagnostic tests. In addition,
unravelling the biological processes involved in the efficient
metastatic spread, characteristic of IBC tumour cells, might lead
to a better understanding of the mechanisms behind breast cancer
metastasis in general. Therefore, efforts were undertaken to gain
deeper insights at molecular level into the biology of IBC. Hence, it
was demonstrated that IBC shows a distinct gene-expression
profile compared to non-IBC (Bertucci et al, 2004; Van Laere et al,
2005). In the present study, this observation was confirmed in a
platform-independent manner, using both principal component
analysis and unsupervised hierarchical clustering. The greatest
variation in gene expression in the present data set is attributable
to the distinction between IBC and non-IBC. Strikingly, the gene-
expression profile of IBC tumours more closely resembles the
gene-expression profile of T1 or T2 tumours instead of T3 or T4
tumours, which might be explained by the fact that IBC tumours
are quickly arising tumours, instead of longstanding tumorigenic
processes. In fact, this observation argues in favour of a non-stage-
matched approach when comparing IBC to non-IBC. The
identification of an IBC-specific gene-expression profile suggests
that some biological processes might be associated with the clinical
presentation discriminating IBC from non-IBC. Since it has been
proven that the tumour stroma-associated gene-expression profile
significantly contributes to the overall gene-expression profile of
breast tumours (Yang et al, 2006), we cannot exclude that tumour/
host interactions play an important role in the clinical presentation
of IBC. Hence, it is, at this point, impossible to say whether the
different gene-expression profile of IBC reflects a different gene-
expression profile of IBC tumour cells, a different constitution of
the tumour-associated stroma or both.
As shown previously, the differences in gene expression,
observed between IBC and non-IBC, are, in part, attributable to
the differential presence of the different cell-of-origin breast cancer
subtypes. Referring to our initial data set, breast tumours from
patients with IBC showed a higher propensity of belonging to the
basal-like or ErbB2-overexpressing cell-of-origin subtype (Van
Laere et al, 2006a). Given the frequent ErbB2 and/or EGFR
Table 2 Global test and GSEA on gene lists of NF-kB related GO-identifiers
GO ID GO term No. of genes tested Global test GSEA
1 GO:0004704 NF-kB-inducing kinase activity 2 0.1212 0.662
2 GO:0007249 I-kB kinase/NF-kB cascade 169 o0.0001 0.624
3 GO:0007250 Activation of NF-kB-inducing kinase 13 0.0001 0.177
4 GO:0007253 Cytoplasmic sequestering of NF-kB 6 0.4838 0.815
5 GO:0008588 Release of cytoplasmic sequestered NF-kB2 0.0175 0.737
6 GO:0042345 Regulation of NF-kB import into nucleus 9 0.0207 0.847
7 GO:0042346 Positive regulation of NF-kB import into nucleus 3 0.0182 0.92
8 GO:0042347 Negative regulation of NF-kB import into nucleus 6 0.4838 0.822
9 GO:0042348 NF-kB import into nucleus 9 0.0207 0.837
10 GO:0043122 Regulation of I-kB kinase/NF-kB cascade 131 o0.0001 0.448
11 GO:0043123 Positive regulation of I-kB kinase/NF-kB cascade 121 0.0001 0.693
12 GO:0043124 Negative regulation of I-kB kinase/NF-kB cascade 8 o0.0001 0.009
13 GO:0051059 NF-kB binding 9 0.3102 0.712
14 GO:0051092 Activation of NF-kB transcription factor 13 0.0001 0.509
GSEA¼gene set enrichment analysis; GO¼gene ontology; NF-kB¼nuclear factor-kappaB.
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soverexpression and the frequent loss of ER protein expression in
IBC, as well as the reduced overall survival for patients with IBC
compared to patients with non-IBC, this observation could not be
regarded as a coincidence. In the same study, however, we also
demonstrated that the specific gene-expression profile of breast
tumours from patients with IBC is not only attributable to the
preferential segregation of these breast tumours in the basal-like or
ErbB2-overexpressing breast cancer subtypes. In fact, only a small
percentage of the specific gene-expression profile of breast
tumours from patients with IBC is cell-of-origin subtype-specific
(Van Laere et al, 2006a). Using a centroid-mediated classification
algorithm to analyse the presence of the different cell-of-origin
breast cancer subtypes in the present data set, we again showed
that breast tumours from patients with IBC significantly more
often belong to the basal-like or ErbB2-overexpressing cell-of-
origin subtypes. The classification of the breast tumour samples
into the different cell-of-origin subtypes was in close agreement
with IHC staining results obtained for ER, PR, ErbB2, EGFR and
CK5/6, thereby validating our classification. As mentioned
previously, the significant overrepresentation of the basal-like or
the ErbB2-overexpressing cell-of-origin subtype in the group of
breast tumours from patients with IBC cannot fully explain
the characteristics associated with IBC, since several IBC speci-
mens clearly show a luminal A, luminal B or normal-like
phenotype. In addition, most basal-like or ErbB2-overexpressing
breast tumours do not present the same clinical characteristics
associated with IBC.
The distinct gene-expression profile of breast tumours from
patients with IBC was translated into an IBC signature, based on
the expression of 756 genes, able to separate IBC from non-IBC in
A E S G O G p o T s tested e n e G # Term GO GOID
1 GO:0004089 Carbonate dehydratase activity 10 <0.0001 0.002
2 GO:0004727 Prenylated protein tyrosine phosphatase activity 6 <0.0001 0.002
3 GO:0005006 Epidermal growth factor receptor activity 12 <0.0001 0.001
4 GO:0003746 Translation elongation factor activity 32 <0.0001 0.344
5 GO:0051010 Microtubule plus-end binding 6 0.0008 0.03
6 GO:0046873 Metal ion transporter activity 58 0.0009 0.277
7 GO:0005010 Insulin-like growth factor receptor activity 7 0.0011 0.005
8 GO:0043548 Phosphoinositide 3-kinase binding 7 0.0011 0.001
9 GO:0004289 Subtilase activity 2 0.0015 0.273
10 GO:0005089 Rho guanyl-nucleotide exchange factor activity 70 0.0018 0.765
11 GO:0043560 Insulin receptor substrate binding 10 0.0023 0.322
12 GO:0015459 Potassium channel regulator activity 14 0.0047 0.072
13 GO:0004155 6,7-dihydropteridine reductase activity 1 0.0074 0.036
14 GO:0015226 Carnitine transporter activity 1 0.0074 0.004
15 GO:0005520 Insulin-like growth factor binding 23 0.0126 0.408
16 GO:0004361 Glutaryl-CoA dehydrogenase activity 2 0.0149 0.039
17 GO:0004853 Uroporphyrinogen decarboxylase activity 2 0.0149 0.136
18 GO:0008330 Protein tyrosine/threonine phosphatase activity 2 0.0149 0.042
19 GO:0005179 Hormone activity 2 0.0171 0.048
20 GO:0008429 Phosphatidylethanolamine binding 3 0.0222 0.049
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Figure 4 SAM plot generated using a d-value of 1.6 to control the FDR at a level of 0.01 (A). Totally, 1794 genes are significantly different in expression
between IBC and non-IBC, from which approximately 53 genes are expected to be false positives. This list of 1794 was intersected with a list of differentially
expressed genes from an earlier study, resulting in 115 commonly overexpressed genes. This gene list was then analysed using the topGO algorithm to
identify molecular functions overrepresented within this gene list. The 20 top-ranked molecular functions are represented in (B). For each GO identifier, we
reported the number of genes tested, as well as the P-value for both topGO analysis and GSEA.
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san unsupervised hierarchical clustering analysis (Van Laere et al,
2005). In the present study, we demonstrate that the IBC signature
truly captures the difference between IBC and non-IBC, since genes
belonging to the IBC signature are significantly overrepresented in
a list of differentially expressed genes generated in a platform-
independent manner, as shown by GSEA. One of the hallmarks of
our IBC signature was the presence of numerous NF-kB target
genes, suggesting NF-kB hyperactivation in IBC (Van Laere et al,
2005, 2006b). In the present data set, the hyperactivation of NF-kB
in breast tumours from patients with IBC was investigated using an
NF-kB signature, described by Loercher et al (2004). Cluster
analysis and global testing demonstrated that NF-kB hyperactiva-
tion was indeed associated with IBC, but, despite this association,
NF-kB hyperactivation is not the main causative molecular
alteration in IBC, as shown by GSEA. Hence, NF-kB hyperactiva-
tion is not specific for IBC, which agrees with previous findings,
that NF-kB hyperactivation is implicated in the generation ER-
negative breast cancer in general (Biswas et al, 2001; Zhou et al,
2005; Van Laere et al, 2007). One possible explanation for the
involvement of NF-kB in ER-negative breast cancer is the
hyperactivation of MAP kinases secondary to EGFR and/or ErbB2
overexpression, leading to an NF-kB-dependent downregulation of
ER expression (Van Laere et al, 2007). In this context, we have
shown that the NF-kB signature performed better in separating
ER-negative breast tumours from ER-positive breast tumours as
well as EGFR- and/or ErbB2-overexpressing breast tumours from
their EGFR-negative and ErbB2-negative counterparts. Hence, with
respect to NF-kB activation, IBC is not a distinct entity but merely
constitutes a minor part of the spectrum of ER-negative breast
tumours.
To gain deeper insight into the mechanisms active in breast
tumours from patients with IBC, we intersected the list of
differentially expressed genes from the former and the present
study. Hence, we identified 115 commonly overexpressed genes
that were analysed to investigate which molecular functions are
represented within this gene list. Different GO-identifiers, linked to
insulin-like growth factor (IGF) signalling were identified. The IGF
pathway has been implicated in cell motility and breast cancer
metastasis (Zhang et al, 2005), both major hallmarks of IBC.
Moreover, loss of IGF-binding protein-related protein (IGFBP-rP9)
is observed in 90% of the IBC specimens (Van Golen et al, 1999),
which leads to increased IGF signalling and activation of RhoC
(Kleer et al, 2004). In cell line experiments, insulin-like growth
factor 1 (IGF1) activates Rho GTPases and IGF1-stimulated cell
motility requires activation of PI3K (Zhang et al, 2005). Interest-
ingly, genes belonging to ‘phosphoinositide 3-kinase binding’ and
‘Rho guanyl-nucleotide exchange factor activity’, molecular func-
tions implicated in respectively PI3K signalling and Rho GTPase
activation, are overrepresented in the list of commonly over-
expressed genes. These data are in agreement with previously
published data on IBC. Altogether, our gene-expression data
provide the fingerprints of a pro-metastatic-signalling pathway,
potentially explaining the highly invasive and metastatic pheno-
type of IBC.
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